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Abstract 
The objective of this study was to devise a rapid mouse model for the in vivo 
screening of new anti Helicobacter pylori products. Six to eight week-old mice pre-
treated (7 days) with Amoxicillin/Metronidazole (25 mg/kg) to eliminate all 
Helicobacter-like organisms were inoculated (4x per week) with 200 µl of a bacterial 
culture (108 CFU/ml of H. pylori CCUG-39500). Colonisation of mouse stomach was 
assessed from day 1 to 15 post inoculation by the Gram stain, rapid urease test and 
antral mucus culture. These findings were used as a mouse model of Helicobacter 
pylori infection to assess the in vivo anti Helicobacter activities of two plant-derived 
molecules with proven cytoprotective, ulcer healing and in vitro anti Helicobacter 
properties (TN, a tabersonine chloride alkaloid from the fruits of Voacanga Africana 
and PAL, a protoberberine alkaloid ((7,8-dihydro-8-hydroxy-palmatine) from the bark 
of Enantia chlorantha). For up to 6 days post inoculation, the test organisms were 
recoverable by culture from 87.5% of  the antral mucus samples while 100% of Gram 
stains were positive. The infection tended to clear naturally from day 9. Fifteen days 
post infection, only Gram stains were still positive (37.5%). Three-day oral 
administration of TN, PAL (50 mg/kg) and Metronidazole (25 mg/kg) completely 
eliminated the bacterial strain from the gastric antral mucus compared with the 
controls. This 4-week model is proposed as a rapid screening tool for in vivo evaluation 
of new anti H. pylori products in order to select candidates for detailed investigations. 
 
Keywords: Helicobacter  pylori, in vivo, mouse model. 
 
Introduction 
Helicobacter pylori (H. pylori), has probably been part of the human gastric 
biota since time immemorial (Blaser, 1997), but its implication in chronic gastritis, 
peptic ulcer disease, gastric cancer as well as mucosa-associated lymphoid tissue 
(MALT) lymphoma has made it a major public health concern (DeCross and Marshall,  
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1993; Graham, 1997; Gibson et al., 1999) since these diseases are major causes of 
death worldwide (Radcliff et al., 1996). Genetic diversity between clinical isolates from 
different populations is one of the most distinctive characteristics of this pathogen 
(Niyaz and Sechi, 2005). These findings have considerably revolutionized the 
management of peptic ulcer disease and gastroduodenal malignancies. H. pylori 
eradication is now a major step in the therapeutic management of these diseases 
(Walsh, 1995; Beales, 2001), and effective treatment of H. pylori-induced peptic ulcer 
disease requires the use of at least two antimicrobial agents (selected among 
Amoxicillin, Metronidazole, Clarithromycin and Tetracycline) combined with antacids 
and/or antisecretory agents (Hentschel et al., 1993; Dunn et al., 1997; Beales, 2001; 
Kanamaru et al., 2001).The  Emergence of H. pylori strains resistant to the 
recommended antibiotics, the associated side effects and low patient compliance,  are 
cited as some of the major causes of treatment failure (Skirrow, 1992; Fauchère, 1999; 
Kato et al., 2000; Okamoto, 2002). Developing new anti-Helicobacter compounds is 
therefore of great importance. 
The literature is rich with information on the in vitro assessment of anti-
Helicobacter properties of medicinal plant products (Nataliya et al. 2000; Yee and Koo, 
2000; Kanamaru et al., 2001; Marone et al., 2001; Mahady et al., 2003a; Mahady et al., 
2003b). However, the therapeutic usefulness of products active in vitro must be 
confirmed by in vivo tests. Although no animal model of H. pylori infection exactly 
mimics the human disease, experimental animal models using primates, domestic cats 
and dogs, gnotobiotic piglets, ferrets, Mongolian gerbils and mice have provided 
important insights into the in vivo evaluation of new antimicrobials. This has increased 
the understanding of host-pathogen relationships and virulence factors of the various 
strains of H. pylori (Danon et al. 1995; Enno et al., 1995; Fox et al., 1995; Sakigami et 
al., 1996; Lee et al., 1997; Lee, 1998; Krakowka et al., 1998; Kanamaru et al., 2001; 
Sgouras et al., 2004). The use of large animals is cumbersome and time-consuming but 
also very expensive and therefore available only to few investigators. Mouse-based H. 
pylori infection models are very useful tools, and for studies to be comparable between 
laboratories, standard criteria (the 1995 Lausanne criteria) were agreed upon. The 
Sydney strain of H. pylori (SS1) has been used successfully for the study of H. pylori 
pathogenesis, vaccine development and for the screening of anti H. pylori products 
(Lee et al., 1997; Lee, 1998; Jenks et al., 1999; Sizemore et al., 2002; Loughlin et al., 
2003; Sgouras et al., 2004). 
Short stomach transit time and poor acid stability render many compounds 
endowed with in vitro anti-Helicobacter properties ineffective in vivo (Haas et al., 
1990; Skirrow, 1992, Krakowka et al., 1998). Although, according to the Lausanne 
criteria, permanent colonisation leading to pathology is a pre-requisite for animal 
models designed to assess host-pathogen relationships and microbial eradication in 
well-established H. pylori-induced disease conditions, this may not necessarily be the 
case when the experimental goal is to screen large numbers of new products for in vivo 
anti Helicobacter activity. In many developing countries, the lack of experimental 
facilities usually hamper the effort of scientists working in this domain. For these 
reasons, we have designed a short-term (two-week) in vivo mouse model that can be 
used for the screening of new anti H. pylori products prior to the selection of candidates 
for more detailed expensive experimentation. This study describes a simplified in vivo 
method for assessing the anti-Helicobacter activity of compounds using the easily- 
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cultured CCUG-39500 H. pylori strain in mice. The paper describes the preparation of 
H. pylori-free mice, the preparation and maintenance of H. pylori bacterial culture, 
confirmation of effective infection of mice with the H. pylori strain and the subsequent 
eradication of the microbes using two test compounds and a standard control drug. 
 
Materials and methods 
Plant materials 
 
The alkaloid (7,8-dihydro-8-hydroxy-palmatine) prepared from Enantia 
chlorantha Oliver,  Annonaceae (voucher specimen N° 25918/SRFCAM) was used. 
(Figure 1). The bark was collected from Edea in the Littoral Province of Cameroon. 
The extraction, isolation and purification of the active compound were done as 
previously reported (Tan et al., 2000). A more detailed report is presented by Wafo et 
al. (1999). The compound was code named PAL . The purified compound prepared 
from the fruits of Voacanga africana Stapf (Apocynaceae) is  an alkaloid (TN) with 
Cameroon National Herbarium voucher specimen N° HNC/ 1949: P. Nana. The fruits 
were harvested in Yaoundé, sun dried and ground to a powder. Detailed preparation 
procedure for TN is reported by Tan and Nyasse (2000). Preliminary chemical and 
physical data suggested that the compound may correspond to tabersonine 
hydrochloride (m.p.192-195; [K]D -307; elemental analysis: C20H26O2N2.HCl) and its 
detailed structural elucidation awaits publication. 
Animals 
 
Six to eight-week old inbred healthy Swiss mice weighing between 17 and 23 g 
were used for the study. To avoid coprophagy, they were housed in raised wire mesh 
bottom cages. The animals were maintained on a 12 h light/dark cycle with water ad 
libitum, and fed with laboratory baked food made of maize (50%), soybeans (25%) and 
wheat flour (25%), supplemented with table salt, palm oil, fish and bone powder. Prior 
authorization for the use of laboratory animals was obtained from the Cameroon 
National Ethics Committee (Reg. No. FWA-IRB00001954). 
 
Culture media, and culture media supplements 
 
Columbia agar (CM0331), Brain Heart Infusion (CM0225), Lacked Horse 
Blood (SR0048), Horse Serum (SR0035), Vitox supplement (SR0090), Helicobacter 
pylori DENT supplement (SR0147) as well as the CampyGen gas pack (CN0024A) 
were all purchased from Oxoid, Basingstoke, England.  
 
The microbial strain 
 
Lyophilised Helicobacter pylori CCUG 39500 was obtained from the Culture  
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Collection University of Göteborg (CCUG), Sweden. The strain was revived using 
Brain Heart Infusion supplemented with 10% horse serum (BHI-serum) and identified 
using the rapid urease and the catalase/oxydase tests (Fauchere, 1999; Dunn et al, 
1997). It was maintained under microaerophilic conditions at 37°C on Columbia agar 
supplemented with 5% (v/v) lacked horse blood and 1% (v/v) Vitox, and subcultured 
every 96 hours to a fresh medium. The microaerophilic conditions were generated 
using CampyGen  in a 2.5 L air-tight anaerobic jar (Oxoid). The isolation of H. pylori 
from mouse stomach biopsies was done on Columbia-DENT agar supplemented with 
5% (v/v) lacked horse blood and 1% (v/v) Vitox (CD-Vitox). The infective inoculum 
was prepared by suspending 72-h colonies in 2 ml of sterile normal saline to make  a 
turbidity standard of McFairland N° 1. The cell suspension of this turbidity standard 
was evaluated by standard plate count and was found to vary from 1.60 x108 to 3.05 x 
108 CFU /ml (Cheesbrough, 1985).  
 
Antibiotics 
Amoxicillin (Amoxyl 500 mg/5 ml) and Metronidazole (Metronidazole USP 
RTU®; 500 mg/100 ml) purchased from a local pharmacy were, respectively, from 
GlaxoSmithKline Australia Pty Ltd. and Baxter Healthcare Corporation, Deerfield. 
Stock solutions were prepared The concentrations used in mice were prepared using 
sterile normal saline. 
Eradication of Helicobacter-like organisms. 
 
In order to ensure that the mice used were free from other Helicobacter-like 
organisms (HLOs), they were pre-treated with a mixture of Amoxicillin (25 mg/kg) and 
Metronidazole (25 mg/kg) administered per os once daily for seven consecutive days in 
a final volume of 200 µl. A preliminary experiment was conducted on 20 animals 
grouped as follows: a test group (5 females and 5 males) treated for seven days with the 
HLO eradication regiment and a control group (5 females and 5 males) treated for 7 
days with 200 µl of sterile normal saline (NaCl 0.9 %). The animals were fasted on the 
8th day after which they were sacrificed.  The stomachs were removed and the antral 
mucus layer was scraped. Part was used to prepare Gram stain slides and part was 
inoculated in urea broth while the remainder was homogenised in a test tube containing 
500 µl of BHI. The homogenate was inoculated by flooding on CA-Vitox -DENT plate. 
The plate was incubated under microaerophilic conditions for five days before 
discarding. The urea broth was incubated in a candle jar for 3 hours after which the 
tubes were observed for any colour change. The Gram stain, urease test and culture 
technique did not reveal the presence of HLOs in both the test and control groups. 
Thus, the antibiotic pre-treatment satisfactorily certified the animals as helicobacter-
free.  
 
Infection of mice with H. pylori CCUG-39500 and assessment of colonisation 
 
Forty-eight mice  Helicobacter-free mice (24 males and 24 females) were 
allowed to rest for a further 7 days  in order to clear the system of circulating  
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antibiotics. Following a 12-h fast, the mice were inoculated per os with 200 µl of 
bacterial culture containing 108 CFU/ml of H. pylori CCUG-39500. The inoculation 
was done four times a week, with a 24-h interval between inoculations. Each 
inoculation was preceded by a 12-h fast. In order to confirm effective infection, six 
groups of 8 mice each (4 males and 4 females) were sacrificed respectively on days 1, 
3, 6, 9, 12, and 15 following the last inoculation. H. pylori colonisation was assessed by 
Gram staining, rapid urease activity, and culturing of samples of the mucus layer of the 
antrum as described above. Positive cultures were further confirmed with the urease, 
catalase and oxydase tests.  
 
Assessment of H. pylori eradication. 
 
Mice (8 per group) infected as described above, were allowed to rest for a day 
after the last inoculation. They were then given the test products orally, once daily for 
three consecutive days. The plant preparations were administered in a final volume of 
500 µl of 0.25% Tween 80 at the dose of 50 mg/kg.  A positive control group was 
treated with Metronidazole (25 mg/kg)  and a negative control group was given 500 µl 
of a sterile solution of 0.25% Tween 80. Following the last day of antibiotic treatment, 
the mice were fasted for 12 h after which they were sacrificed. The stomachs were 
excised and H. pylori clearance was assessed by Gram staining, rapid urease test and 
culture as described above. 
 
Results 
Assessment of H pylori CCUG-39500 infection of the mice 
 
In order to make sure that the animals used for the experiment were 
Helicobacter-free, all were pre-treated with an eradication regimen (Amoxicillin and 
Metronidazole) before infection with the experimental strain of H. pylori. The 
assessment of evidence of colonisation with H. pylori CCUG-39500 was 
simultaneously done by Gram staining, and the rapid urease test and culture for 
isolation of viable H. pylori. A slight change in the colour of the urease test tube within 
3 hours was considered as positive. Some of the tubes showed a clear pink colour after 
1 to 2 h but in some tubes a pale pink colour could be observed after three hours. There 
was therefore variation in the speed and the intensity of the urease reaction. From the 
1st to the 6th day, evidence of colonisation was demonstrated by the Gram stain, rapid 
urease test and the culture technique (Table 1). The infection began to clear from the 
stomachs of 5 out of the 8 animals 9 days after inoculation with the bacterial culture. 
This was shown by negative cultures and urease tests. However, the Gram staining 
technique still revealed the presence of curved Gram negative bacteria in the smears 
prepared from the stomachs of all the group 4 animals sacrificed on day 9. Although 
the Gram stain continued to reveal the presence of infection in 5 to 6 animals (62.5 – 
75%) up to day 15, the urease test and culture plates did not reveal signs of infection as 
of day 12 post inoculation.  No apparent differences were noticed between male and 
female mice in infectivity with the microbe or onset of clearance from the stomachs.  
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Table 1: Assessment of the presence of H. pylori in the mouse stomach after infection 
with H. pylori CCUG39500 
 
  Day 1  (Group I) 
Day 3  
(Group 2) 
Day 6    
(Group 3) 
Day 9  
(Group 4) 
Day 12 
(Group 5) 
Day 15 
(Group 6) 
  G U C G U C G U C G U C G U C G U C 
1 + + + + + + + + + + + − + − − + − − 
2 + + + + + + + + + + + + + − − + − − 
3 + + + + + + + + + + + + + − − + − − 
4 + + + + + + + + + + + − − − − − − − 
5 + + + + + + + + − + − − + − − + − − 
6 + + + + + + + + + + − − − − − − − − 
7 + + + + + + + + + + + + + + − + − − 
A
ni
m
al
 N
° 
8 + + + + + + + + + + + − + − − − − − 
% 
positive 100 100 100 100 100 100 100 87.5 87.5 100 75 37.5 62.5 12.5 00 62.5 00 00 
 
G: Gram staining 
U: Rapid Urease test 
C: Culture  
+: positive test or reaction 
−: Negative test or reaction 
Animals: No.1 to 4 are males;  No. 5 to 8 are females. Group 1-6 animals were sacrificed on day 1, 3, 6, 
9,12 and 15, respectively, post infection. 
 
 
In vivo eradication of H. pylori CCUG-39500 in mice 
 
This assay was done in order to assess the ability of compounds with proven in 
vitro H. pylori activities to rid the stomach antrum of H. pylori following in vivo 
treatment. All the animals in the negative control group were successfully infected with 
H. pylori throughout the test period and the treatment with 0.25% (v/v). Tween 80, 
500µl daily did not eradicate the pathogen (Table 2, Plate 1). In contrast, the cultures of 
the gastric tissue samples from the infected mice treated with PAL and TN as well as 
Metronidazole did not yield any growth after three days of treatment (Table 2; Plates 2 
- 4). In the group treated with TN, the Gram stain, the rapid urease test, as well as the 
tissue cultures were negative for all the 8 animals. Positive Gram stains were obtained 
in one case for PAL and in two cases for Metronidazole.  
 
Discussion 
Studies on the ecology of Helicobacter have proposed that various animal 
species harbour specific Helicobacter species. Thus, H. pylori, H. felis, H. mustelae, 
and  H. heilmannii  are  species  adapted  to   man,  cats/dogs,  ferrets   and     primates,  
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Table 2: Assessment of H. pylori clearance from mouse stomach following three days 
of treatment with TN, PAL and metronidazole.  
 
  PAL 50 mg/kg BW 
TN 50 mg/kg 
BW 
Metronidazole 25 
mg/kg BW 
Control (0.25% 
(v/v) Tween 80) 
  G U C G U C G U C G U C 
1 − − − − − − − − − + + + 
2 − − − − − − − − − + + + 
3 − − − − − − − − − + + + 
4 − − − − − − − − − + + + 
5 + − − − − − − − − + + + 
6 − − − − − − + − − + + + 
7 − − − − − − − − − + + + A
ni
m
al
 N
o.
 
8 − − − − − − + − − + + + 
% Negative 87.5 100 100 100 100 100 75 100 100 0 0 14 
 
  G: Gram stain 
U: Rapid Urease test 
C: Culture  
+: positive test or reaction 
: Negative test or reaction 
Animals: No.1 to 4 are males;  No. 5 to 8 are females. 
 
 
N
OCH3
OCH3
OH
H3CO
H3CO
PAL
 
Figure 1: Chemical structure of PAL (7,8-dihydro-8-hydroxy-palmatine) 
 
respectively. (Stephen Danon et al., 1995). This notwithstanding, primates have been 
known to become infected with H. pylori, mouse models of H. felis which mimic the 
human pathology have been developed, a colony of SPF cats has been infected with a 
H. pylori isolate, and H. heilmannii is also known to be a natural feline Helicobacter     
( Lee, 1998; Enno et al., 1995; Lee et al., 1990). Although early studies showed that 
mice could not be infected by clinical isolates of H. pylori, Lee et al. (1997) quickly 
developed a mouse model using a human clinical isolate, the “Sydney strain” of H.  
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Plate 1: Photograph of a positive Gram stain of the 
control mucous layer, after treatment for three days with 
0.25% (v/v) Tween 80. Arrows indicate the Gram 
negative curved bacteria (H. pylori). 
Plate 2: Photograph of a negative Gram stain of the 
mucous layer, after treatment for three days with 
Metronidazole (25 mg/kg body).  
 
 
 
 
 
 
 
 
 
 
Plate 3: Photograph of a negative Gram stain of the 
mucous layer, after treatment three days with TN (50 
mg/kg). 
Plate 4: Photograph of a negative Gram stain of the 
mucous layer, after treatment three days with PAL 
(50 mg/kg). 
 
pylori. This is a cagA, vacA positive strain which has been widely used satisfactorily in 
Helicobacter-related peptic ulcer research.   
We have recently carried out an in vitro screening study of the antimicrobial 
activity against Helicobacter pylori (CCUG 39500) and Campylobacter jejuni-coli 
using 69 crude extracts obtained from Cameroonian medicinal plants (Tan et al., 
unpublished). The in vitro antimicrobial actions of the pure compounds used in the 
present study have also been demonstrated (Tan et al., unpublished). Unfortunately, 
these results can not be relied on as evidence of in vivo activity. Because of the high 
cost of equipment and instrumentation necessary to work in in vivo conditions that 
conform strictly to the Lausanne criteria of H. pylori experimentation, only few 
laboratories are privileged to work in this domain.  For example, 1 – 2 months are 
needed after inoculation before colonisation with the Sydney strain of H. pylori is 
assessed, and it takes up to 8 months before a histologically-detectable chronic active 
gastritis develops in mice (Lee et al., 1997). For this reason, it would be of  advantage  
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during massive screening exercises to use  a low-cost short-term model that can 
demonstrate the antimicrobial potencies of new products in vivo. A select number of 
highly active products can then be used as candidates for detailed work involving 
pathology in collaboration with advanced laboratories.  
The H. pylori strain used (the CCUG 39500 strain) is a human species that 
corresponds to the ATCC 43504 and NCTC  11637 strains (CCUG Web site a & b) 
which are routinely used for in vitro work largely due to their ease of cultivation (Best 
et al., 2003; Hassan et al., 1999; Svenson et al., 2002; Takeshi et al., 2002). Following 
CCUG instructions, the microbe was successfully revived and maintained in culture 
with regular sub culturing every 72 hours. All standard microbiological techniques for 
culture and assessment of colonisation were observed. However, the results obtained 
showed that the microbe was able to colonise the stomach mucous layer for up to 15 
days maximum in contrast to the long-term colonisation usually obtained with the SS1 
strain. Thus, the CCUG strain, although a human pathogen, is unable to withstand the 
mouse defence mechanism beyond two weeks and therefore cannot survive long 
enough in the mouse to induce pathological gastritis. However, the length of time the 
microbe survived in the mouse offers a window of opportunity to test the antimicrobial 
effect of anti-Helicobacter products under in vivo conditions. Thus, the decision to dose 
the animals with the antimicrobial products from days 2 to 4 post inoculation was based 
on the certainty of effective presence of the pathogen in the mucous layer within this 
period as shown by the Gram stain, urease and culture tests (Table 1). The SS1 strain 
can be left for up to one week after inoculation after which a two-week antimicrobial 
therapy is conducted (Lee et al., 1997). Thus, H. pylori CCUG-39500 is a human 
gastric mucosa-adapted strain of H. pylori, that is not adapted to mice for use in the 
study of the mechanism of chronic gastritis and gastric malignancy associated with H. 
pylori infection and to understand the pathogenesis of the infection. It may be 
necessary therefore to conduct pilot experiments order to ascertain the exact window of 
the short infection period that can be exploited for antimicrobial assessment using the 
CCUG-39500 strain. Since complete clearance of a standard H. pylori strain from the 
stomach was obtained during the treatment period, further quantitative analysis was not 
employed in order to detect its presence. However, it is suggested that in using the 
present model, quantitative evaluation, especially for new products showing partial 
clearance, should be carried out. 
Important insights into bacterial factors governing the colonisation as well as 
the host factors associated with the development of pathology have been provided by 
several animal models (Danon et al. 1995, Enno et al., 1995; Fox et al., 1995; Sakigami 
et al., 1996; Lee et al., 1997; Krakowka et al., 1998; Lee, 1998). For the in vivo 
assessment of anti Helicobacter compounds, mice and Mongolian gerbils are most 
often used (Kanamaru et al., 2001; Sgouras et al., 2004). However, there is no animal 
model of H. pylori infection that exactly mimics the human disease (Lee, 1998). 
The in vivo antimicrobial tests carried out using this short-term mouse model 
confirm the activity of metronidazole as an antibiotic of choice in H. pylori eradication 
therapy. The results show that in addition to the in vitro activity of PAL and TN, these 
new compounds also have in vivo antibacterial effects. The gastric anti-secretory 
activity of TN similar to that of H2 receptor blockers of histamine has been shown, and 
the ulcer healing properties of these compounds are associated with an enhancement of  
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gastric mucus production (Tan et al., 2000; Tan and Nyasse, 2000). In  combination 
with ranitidine, PAL and TN have also exhibited potentiating and synergistic 
antisecretory effects, respectively (Tan et al., 2002). The combined ulcer healing and 
antimicrobial potencies of these compounds enlist them as possible future candidates 
for the formulation of monotherapy antiulcer regimens with improved patient 
compliance. 
Positive results obtained from in vitro screening of extracts for anti 
Helicobacter activity do not constitute absolute proof of eventual in vivo efficacy. 
Thus, in spite of the obvious limitation of the present model which consist in the 
inability of the CCUG 39500 strain to colonize the mouse gastric mucous layer beyond 
two weeks, it nevertheless offers the opportunity for the short-term rapid screening of 
new plant products under in vivo conditions. Possible candidates for more detailed 
investigations can thus be selected at low cost. 
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